
    
      This is a double-blind, placebo-controlled, investigator-initiated randomized trial to
      evaluate the impact of MS-20 on gut microbiota composition and abundance in healthy people.
      Approximately 100 subjects who meet the criteria of this study are planned to be enrolled.
      Eligible subjects will be randomized to receive placebo or MS-20 in a 1:1 ratio with 50
      subjects in each arm.

      The study comprises of a 7 days screening period, a 8-week treatment period and a 8-week
      follow-up period. Eligible subjects will receive MS-20 or placebo every day during the
      treatment period. Participants should not use any probiotics and prebiotics during the trial.
      In addition, All medications (especially antibiotics) should be recorded and documented,
      however, fluoroquinolones and vancomycin will be banned during the trial.

      The fecal gut microbiota, serum, and urea were collect at indicated time. The gut microbiota
      composition, gut microbiota metabolite, and serum biochemical items will be analysed.
    
  